Pfizer's (PFE) Sutent Significantly Improved Progression-Free Survival for Patients with Advanced Pancreatic Islet Cell Tumors
More News related to PFE
- Trading Outlook for Advanced Life Sciences Holdings Inc. Issued by InvestorSoup.com
- Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX(R) (Varenicline) Compared With Placebo
- Flamel Technologies Announces Licensing Agreement with Pfizer
- Pfizer (PFE) And Medivation (MDVN) Initiate Two Phase 3 Trials Of Dimebon
- Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer's Disease
Pfizer (NYSE: PFE) announced results from a randomized Phase 3 trial of Sutent (sunitinib malate) in patients with advanced pancreatic islet cell tumors, also known as pancreatic neuroendocrine tumors, which is a different type of cancer than the more common pancreatic adenocarcinoma. Study findings demonstrated that median progression-free survival (PFS) was 11.1 months in patients treated with Sutent compared to 5.5 months in patients treated with placebo. Researchers today presented these data at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The independent Data Monitoring Committee (DMC) recommended halting the trial earlier this year because Sutent showed significant benefit and the study had met its primary endpoint. Full analysis of the data is ongoing.
Related Categories
Corporate NewsFDA
Stocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
